Business Context and Reporting Period
Company: ARDELYX, INC. (Nasdaq: ARDX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of tenapanor-based therapies. Its primary products are IBSRELA (for irritable bowel syndrome with constipation) and XPHOZAH (for reducing serum phosphorus in chronic kidney disease patients on dialysis). The company is also advancing a pipeline including a Phase 3 trial for chronic idiopathic constipation (CIC) and a next-generation NHE3 inhibitor, RDX10531.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 | Q2 2025 | 6M 2026 | 6M 2025 |
|---|---|---|---|---|
| Total Revenues | $120,877 | $97,662 | $215,350 | $171,776 |
| Product Sales, Net | $118,129 | $90,077 | $211,502 | $157,891 |
| Net Loss | $(16,721) | $(19,079) | $(54,326) | $(60,223) |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.08) | $(0.22) | $(0.25) |
| Cash and Cash Equivalents | $97,191 | $67,999 | $97,191 | $67,999 |
| Total Liquid Funds (Cash + Short-term Inv) | $281,830 | $264,689 | $281,830 | $264,689 |
| Long-Term Debt (Principal) | $250,000 | $200,000 | $250,000 | $200,000 |
| Accumulated Deficit | $(1,001,265) | $(946,939) | $(1,001,265) | $(946,939) |
Operating Cash Flow (6 Months): Net cash used in operating activities was $38.6 million for the six months ended June 30, 2026, an improvement from $63.8 million in the prior year period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 24% year-over-year in Q2 2026 and 25% for the six-month period. Product sales, net grew 31% in Q2 and 34% for the six months.
- Product Performance:
- IBSRELA: Net sales increased 33% in Q2 and 43% for the six months, driven by higher demand and prescriber experience.
- XPHOZAH: Net sales increased 27% in Q2 and 14% for the six months. Growth remains impacted by the inclusion of XPHOZAH in the ESRD PPS (effective Jan 1, 2025), which eliminated Medicare Part D coverage.
- Expense Increases:
- R&D Expenses: Increased 67% in Q2 and 51% for the six months, primarily due to external costs for the Phase 3 CIC trial and pipeline expansion.
- SG&A Expenses: Increased 21% in Q2 and 22% for the six months, driven by commercialization costs to support IBSRELA growth and increased headcount.
- Debt Financing: On June 29, 2026, the company drew down an additional $50 million under the Term F Loan, bringing total outstanding principal to $250 million. The company also entered into a Sixth Amendment to its Loan Agreement in April 2026, extending maturities to July 1, 2030, and reducing interest rates.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects available cash and investments ($281.8 million) to fund operations for at least one year. The company is prioritizing IBSRELA growth, XPHOZAH commercial momentum, and pipeline advancement (CIC Phase 3 trial enrollment expected to complete by end of 2026).
- Key Risks:
- Reimbursement: Continued lack of Medicare Part D coverage for XPHOZAH due to ESRD PPS inclusion is expected to result in a materially lower pace of revenue growth compared to pre-2025 expectations. A lawsuit challenging this classification was dismissed by the Court of Appeals on June 26, 2026.
- Manufacturing: Complete reliance on third-party CMOs, including single-source suppliers, creates supply chain vulnerability.
- Debt Covenants: The Loan Agreement includes a financial covenant requiring net product revenue plus unrestricted cash to be at least 100% of outstanding principal.
- Unusual Items:
- Collaboration Termination: The exclusive license agreement with Knight Therapeutics for Canada was terminated in March 2026; sales in Canada were discontinued. The termination had no material financial impact.
- Legal Proceedings: Several shareholder derivative and securities class actions were dismissed or settled in 2025 and early 2026. No pending litigation is expected to have a material adverse effect.
Investor Verification Checklist
- Debt Covenant Compliance: Verify that the sum of trailing six-month net product revenue plus unrestricted cash meets the 100% principal coverage requirement under the SLR Loan Agreement.
- XPHOZAH Revenue Trajectory: Monitor the impact of the ESRD PPS bundled payment on XPHOZAH growth rates, specifically the shift from pharmacy benefit to dialysis facility payment models.
- Cash Burn Rate: Assess the sustainability of the current operating cash burn (~$38.6M for 6 months) against the $281.8M liquid balance and the $50M remaining borrowing capacity (Term G Loan).
- CIC Trial Progress: Track enrollment milestones for the ACCEL Phase 3 trial (tenapanor for CIC), with topline data expected in H2 2027.
- Supply Chain Resilience: Review the status of single-source CMOs and any potential disruptions related to the U.S. BIOSECURE Act or geopolitical tensions.